These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34830081)

  • 1. A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with
    Pierzchlińska A; Droździk M; Białecka M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.
    Zhou Y; Tashiro J; Kamatani S; Irie N; Suzuki A; Ishikawa T; Warita K; Oltvai ZN; Warita T
    Biochem Biophys Res Commun; 2023 Oct; 677():13-19. PubMed ID: 37541087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Polymorphisms in the
    Pierzchlińska A; Sławek J; Kwaśniak-Butowska M; Malinowski D; Komaniecka N; Mak M; Czerkawska A; Kukowka A; Białecka M
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional expression of human HMG-CoA reductase in Saccharomyces cerevisiae: a system to analyse normal and mutated versions of the enzyme in the context of statin treatment.
    Wysocka-Kapcinska M; Lutyk-Nadolska J; Kiliszek M; Plochocka D; Maciag M; Leszczynska A; Rytka J; Burzynska B
    J Appl Microbiol; 2009 Mar; 106(3):895-902. PubMed ID: 19187128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
    Yarmolinsky J; Bull CJ; Vincent EE; Robinson J; Walther A; Smith GD; Lewis SJ; Relton CL; Martin RM
    JAMA; 2020 Feb; 323(7):646-655. PubMed ID: 32068819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration.
    Saeedi Saravi SS; Saeedi Saravi SS; Arefidoust A; Dehpour AR
    Metab Brain Dis; 2017 Aug; 32(4):949-965. PubMed ID: 28578514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
    Liu G; Shi M; Mosley JD; Weng C; Zhang Y; Lee MTM; Jarvik GP; Hakonarson H; Namjou-Khales B; Sleiman P; Luo Y; Mentch F; Denny JC; Linton MF; Wei WQ; Stein CM; Feng Q
    JAMA Netw Open; 2021 Jun; 4(6):e2112820. PubMed ID: 34097045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.
    Perchellet JP; Perchellet EM; Crow KR; Buszek KR; Brown N; Ellappan S; Gao G; Luo D; Minatoya M; Lushington GH
    Int J Mol Med; 2009 Nov; 24(5):633-43. PubMed ID: 19787197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
    Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
    Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin inhibition of HMG-CoA reductase: a 3-dimensional view.
    Istvan E
    Atheroscler Suppl; 2003 Mar; 4(1):3-8. PubMed ID: 12714031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
    Osaki Y; Nakagawa Y; Miyahara S; Iwasaki H; Ishii A; Matsuzaka T; Kobayashi K; Yatoh S; Takahashi A; Yahagi N; Suzuki H; Sone H; Ohashi K; Ishibashi S; Yamada N; Shimano H
    Biochem Biophys Res Commun; 2015 Oct; 466(3):536-40. PubMed ID: 26381177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
    Medina MW
    Discov Med; 2010 Jun; 9(49):495-9. PubMed ID: 20587337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG-CoA reductase is a potential therapeutic target for migraine: a mendelian randomization study.
    Qu K; Li MX; Yu P; ; Wu BH; Shi M; Dong M
    Sci Rep; 2024 May; 14(1):12094. PubMed ID: 38802400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HMG-CoA Reductase as Target for Drug Development.
    Gunasekaran B; Shukor MY
    Methods Mol Biol; 2020; 2089():245-250. PubMed ID: 31773659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin therapy inhibits fatty acid synthase via dynamic protein modifications.
    Trub AG; Wagner GR; Anderson KA; Crown SB; Zhang GF; Thompson JW; Ilkayeva OR; Stevens RD; Grimsrud PA; Kulkarni RA; Backos DS; Meier JL; Hirschey MD
    Nat Commun; 2022 May; 13(1):2542. PubMed ID: 35538051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
    Lipkin SM; Chao EC; Moreno V; Rozek LS; Rennert H; Pinchev M; Dizon D; Rennert G; Kopelovich L; Gruber SB
    Cancer Prev Res (Phila); 2010 May; 3(5):597-603. PubMed ID: 20403997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current insights into pathogenesis of Parkinson's disease: Approach to mevalonate pathway and protective role of statins.
    Saeedi Saravi SS; Saeedi Saravi SS; Khoshbin K; Dehpour AR
    Biomed Pharmacother; 2017 Jun; 90():724-730. PubMed ID: 28419968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.
    Donnelly LA; Doney AS; Dannfald J; Whitley AL; Lang CC; Morris AD; Donnan PT; Palmer CN
    Pharmacogenet Genomics; 2008 Dec; 18(12):1021-6. PubMed ID: 18815589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease.
    Cheng KK; Swallow DM; Grosset KA; Grosset DG
    Scott Med J; 2017 Aug; 62(3):104-109. PubMed ID: 28836927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.